Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • 5-HT Receptor
    (1)
  • Adenosine Receptor
    (2)
  • Arrestin
    (1)
  • CaSR
    (2)
  • Calcium Channel
    (1)
  • Cannabinoid Receptor
    (1)
  • Dopamine Receptor
    (1)
  • GABA Receptor
    (2)
  • GluR
    (4)
  • Others
    (24)
Filter
Search Result
Results for "orthosteric" in TargetMol Product Catalog
  • Inhibitor Products
    40
    TargetMol | Activity
  • Recombinant Protein
    2
    TargetMol | inventory
  • Natural Products
    1
    TargetMol | natural
Cloransulam-methyl
T20941147150-35-4
Cloransulam-methyl is an effective herbicide that is often applied to soybean fields to control broadleaf weeds.Cloransulam-methyl is rapidly metabolised in the soybean plant but is present in the soil.CBiPES hydrochloride (CBiPES HCl) is a potent orthosteric modulator of the mGlu2 receptor.
  • $95
In Stock
Size
QTY
TargetMol | Inhibitor Sale
BRD4 Inhibitor 31
T5004856369-21-2
4,4-dimethyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-2-one is a benzodiazepine derivative. It is an orthosteric modulator of the GABAA receptor and selectively binds to the benzodiazepine site of the GABAA receptor. It has anxiolytic, anticonvulsant and sedative activity.
  • $52
In Stock
Size
QTY
TargetMol | Inhibitor Sale
CBiPES hydrochloride
T22638856702-40-4
CBiPES hydrochloride (CBiPES HCl) is a potent orthosteric modulator of the mGlu2 receptor with an EC50 value of 92.8 nM.CBiPES hydrochloride blocks the action of WT and mGlu(3) receptors.CBiPES hydrochloride can be used to study neurological disorders like epilepsy and Parkinson's syndrome. CBiPES hydrochloride can be used to study neurological disorders like epilepsy and Parkinson's syndrome.
  • $173
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Upacicalcet
T290671333218-50-0In house
Upacicalcet (AJT-240) is an intraventricular calcium mimetic, a SHPT available for human hemodialysis, that inhibits excessive parathyroid hormone (PTH) secretion by directly acting on parathyroid cell membrane calcium-sensitive receptors, thereby lowering blood levels of PTH.Upacicalcet is an orthosteric modulator of calcium-sensitive receptors and prevents adenine-induced secondary vascular calcification and bone disease in a rat model of adenine-induced secondary hyperparathyroidism.
  • $110
In Stock
Size
QTY
TargetMol | Inhibitor Sale
LUF6096
T91801116652-18-6In house
LUF6096 (CF-602) is a potent allosteric enhancer of the adenosine A3 receptor, exhibiting the capability to enhance agonist binding allosterically while demonstrating low orthosteric affinity across adenosine receptors. It displays protective effects in myocardial ischemia/reperfusion injury.
  • $49
In Stock
Size
QTY
Calindol hydrochloride
T21758729610-18-8In house
Calindol hydrochloride is a potent orthosteric modulator (EC50: 132 nM) of the putative calcium-calcium-sensitive receptor (CaSR), inhibits Pi-induced VC, and delays the progression of calcification in vascular smooth muscle cells.
  • $63
In Stock
Size
QTY
AC265347
T295411253901-26-6
AC265347 is a potent calcium-sensitive receptor (CaSR) agonist and ago-PAM orthosteric modulator with antitumour activity that inhibits neuroblastoma tumour growth by inducing differentiation.AC265347 can be used to study neuroblastoma.
  • $77
In Stock
Size
QTY
TargetMol | Inhibitor Sale
SR 16832
T248272088135-12-8
SR 16832 is a dual-site PPARγ inhibitor. It also inhibits the binding of endogenous ligands and transcriptional activity of PPARγ, more effectively than the orthosteric covalent antagonist GW 9662 and T 0070907.
  • $30
In Stock
Size
QTY
TargetMol | Inhibitor Sale
5-Benzyloxygramine
T358411453-97-0
5-Benzyloxygramine is a N protein PPI orthosteric stabilizer that exhibits both antiviral and N-NTD protein-stabilizing activities[1]. 5-benzyloxygramine stabilizes the N-NTD dimers through simultaneous hydrophobic interactions with both partners, resulting in abnormal N protein oligomerization that was further confirmed in the cell[1]. [1]. Shan-Meng Lin, et al. Structure-Based Stabilization of Non-native Protein-Protein Interactions of Coronavirus Nucleocapsid Proteins in Antiviral Drug Design. J Med Chem. 2020 Mar 26;63(6):3131-3141.
  • $49
In Stock
Size
QTY
TargetMol | Inhibitor Sale
HCAR2 agonist 1
T822331066676-21-8
HCAR2 agonist 1 (Compound 9n), a G i protein-biased allosteric modulator of HCAR2, activates the G i protein signaling pathway and exhibits anti-inflammatory properties by reducing mRNA levels of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, and MCP-1). Additionally, it potentiates the anti-inflammatory effects of orthosteric agonists in a mouse model of colitis [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
GNE-9278
T623762315311-83-0
GNE-9278 is a highly selective NMDAR orthosteric modulator that acts on the GluN1 transmembrane structural domain (TMD).GNE-9278 acts on activated NMDAR and increases peak current and agonist affinity.
    7-10 days
    Inquiry
    VU0422288
    T291351630936-95-6
    VU0422288 (ML396) is a potent orthosteric modulator of type III mGlu receptors (mGlus).VU0422288 shows inhibition of mGluR4, mGluR7, and mGluR8 in a calcium mobilization assay.VU0422288 can be used to study Rett syndrome (RTT).
    • $73
    In Stock
    Size
    QTY
    GAT100
    T703011663564-42-8
    GAT100 is a potent and covalent negative allosteric modulator (NAM). GAT-100 behaved as a robust positive allosteric modulator of binding of orthosteric agonist CP55,940. This novel covalent probe can serve as a useful tool for characterizing CB1R allosteric ligand-binding motifs.
    • $1,820
    8-10 weeks
    Size
    QTY
    ZCZ011
    T292061998197-39-9
    ZCZ011 is a positive allosteric modulator of the cannabinoid CB1 receptor. ZCZ011 is brain penetrant, increased the potency of orthosteric agonists in mouse behavioral assays indicative of cannabimimetic activity, including antinociception, hypothermia, c
    • $882
    6-8 weeks
    Size
    QTY
    ML381
    T280701623481-80-0
    ML381 is a M5-orthosteric antagonist with a high selectivity of muscarinic subtype.
    • $954
    6-8 weeks
    Size
    QTY
    CB1R Allosteric modulator 1
    T620162513102-41-3
    CB1R Allosteric modulator 1 (compound 11) is a potent allosteric modulator of CB1R. CB1R Allosteric modulator 1 negatively affects the functional activity of orthosteric ligands (NAM) at CB1Rs.
    • $1,520
    6-8 weeks
    Size
    QTY
    nAChR modulator-1
    T743961902218-84-1
    nAChR modulator-1, a insecticide, is a insect nAChR orthosteric modulator [1] .
    • Inquiry Price
    Size
    QTY
    nAChR modulator-2
    T743971700657-87-9
    nAChR modulator-2, a insecticide, is a insect nAChR orthosteric modulator [1] .
    • Inquiry Price
    Size
    QTY
    Padsevonil
    T164271294000-61-5
    Padsevonil (UCB-0942) is a potential GABA A receptor orthosteric modulator with antiepileptic activity for the treatment of epilepsy.
    • $249
    In Stock
    Size
    QTY
    LY593093
    T279611108748-12-4
    LY593093 is a selective partial orthosteric agonist of M1 muscarinic acetylcholine receptor.
    • $1,670
    6-8 weeks
    Size
    QTY
    LY3154885
    T626102379422-72-5
    LY3154885 is an orally active dopamine D1 receptor orthosteric modulator (PAM) that reduces the risk of drug-drug interactions (DDI).
    • $2,140
    8-10 weeks
    Size
    QTY
    Tetrahydrodeoxycorticosterone
    T37725567-03-3
    Tetrahydrodeoxycorticosterone(Tetrahydro-11-deoxycorticosterone) is a potent GABAA receptor orthosteric modulator (PAM) with neuroprotective activity that selectively inhibits neurosteroid-mediated enhancement of GABA-induced currents at the GABAA receptor, and can be used in the study of neurological disorders.
      7-10 days
      Inquiry
      LY 541850
      T11906852679-76-6
      LY541850 is a selective orthosteric mGlu2 agonist and mGlu3 antagonist with IC50 values of 0.161 μM and 0.038 μM, respectively.LY 541850 is claimed from human ionotropic and metabotropic glutamate (mGlu) receptors expressed in non-neuronal cells.
      • $2,570
      10-14 weeks
      Size
      QTY
      MOMBA
      T839556880-04-2
      MOMBA is a selective orthosteric agonist specifically targeting engineered human free fatty acid 2 (hFFA2) receptors, particularly those modified as designer receptors activated by designer drugs (DREADD). It demonstrates selective inactivity towards wild-type hFFA2, hFFA3, and mouse FFA2 receptors. It efficiently inhibits forskolin-induced cAMP levels in cells equipped with the hFFA2-DREADD receptor, exhibiting enhanced potency and comparable efficacy to Sorbic acid. In transgenic mice containing the hFFA2-DREADD gene, MOMBA administration notably slows gut transit and facilitates a concentration-dependent enhancement of GLP-1 secretion from colonic crypts, all while being orally bioavailable.
      • $173
      35 days
      Size
      QTY
      GAT564
      T61180
      GAT564 (Compound 15d) is a highly effective allosteric modulator of cannabinoid 1 receptor (CB1R), having EC50 values of 87 nM and 320 nM for cAMP and β-arrestin2, respectively. It significantly enhances the binding of orthosteric ligands to hCB1R. Moreover, GAT564 exhibits remarkable efficacy as a topical agent, resulting in a significant reduction of intraocular pressure (IOP) in an ocular normotensive murine model of glaucoma [1].
      • $1,520
      10-14 weeks
      Size
      QTY
      Mevidalen HBA
      T703261638669-32-5
      Mevidalen, also known as LY3154207, is a novel, potent, and subtype selective human D1 positive allosteric modulator (PAM) with minimal allosteric agonist activity (EC50 = 3 nM). In contrast to orthosteric agonists, LY3154207 showed a distinct pharmacological profile without a bell-shaped dose-response relationship or tachyphylaxis in preclinical models. Identification of a crystalline form of free LY3154207 from the discovery lots was not successful. Instead, a novel cocrystal form with superior solubility was discovered and determined to be suitable for development. LY3154207 is now in clinical development as a potential first-in-class D1 PAM for Lewy body dementia..
      • $2,270
      10-14 weeks
      Size
      QTY
      CAM833
      T637172758364-02-0
      CAM833 is a potent orthosteric inhibitor of the interaction between BRCA2 and RAD51 and also inhibits RAD51 oligomerization and is able to act on the ChimRAD51 protein (Kd: 366 nM).
      • $1,400
      6-8 weeks
      Size
      QTY
      GAT211
      T27405102704-40-5
      GAT211 (AZ-4) is a selective and potent cannabinoid 1 receptor (CB1R) orthosteric modulator (PAM) with high affinity for cAMP and β-arrestin2.GAT211 has IOP-lowering and antipsychotic effects and can be used in the study of epilepsy.
      • $30
      In Stock
      Size
      QTY
      PF-06256142
      T124231609583-14-3
      PF-06256142 is a potent and selective orthosteric D1 receptor agonist(D1 EC50=30 nM ).
      • $1,400
      6-8 weeks
      Size
      QTY
      LY2979165
      T158121311385-32-6
      LY2979165 (mGlu2 agonist) is an orthosteric agonist of mGluR2 and can be used in studies about serving as an anti-depressant.
      • $68
      In Stock
      Size
      QTY
      Dimethyl-W84 (dibromide)
      T38111402475-33-6
      Dimethyl-W84 is a selective allosteric modulator of the M2 muscarinic acetylcholine receptor. It hinders the dissociation of the orthosteric antagonist N-methylscopolamine from the M2 receptor with an EC50 value of 3 nM.
      • $353
      35 days
      Size
      QTY
      VU6019650
      T73272
      VU6019650 is a potent and selective orthosteric antagonist of M5 mAChR ( IC 50 =36 nM), can be used for opioid use disorder (OUD) relief. VU6019650 can cross blood brain barrier, potentially modulates the mesolimbic dopaminergic reward circuitry. VU6019650 blocks Oxotremorine M iodide induced increases of neuronal firing rates of midbrain dopamine neurons in the ventral tegmental area (VTA) [1] [2] .
      • $1,820
      8-10 weeks
      Size
      QTY
      BMS-681
      T695232760844-13-9
      BMS-681 is an orthosteric antagonist of chemokine receptor 2 (CCR2) that forms a ternary complex with CCR2 and its allosteric antagonist, CCR2-RA-[R]. Together, the complex inhibits chemokine binding with BVMS-681 in the orthosteric pocket and CCR2-RA-[R] in the intracellular allosteric G-protein binding site. When chemokine binding is inhibited, modulation responses implicated in several inflammatory and neurodegenerative diseases, including atherosclerosis, multiple sclerosis, asthma, neuropathic pain, diabetic nephropathy, and cancer can be controlled. This action occurs as the migration of monocytes, immature dendritic cells, and T-cell subpopulations towards endogenous CC chemokine ligands is mediated.
      • $3,470
      10-14 weeks
      Size
      QTY
      KI-7
      T92381489263-00-4
      KI-7 is an adenosine A2B receptor positive allosteric modulator.
      • $38
      In Stock
      Size
      QTY
      GLP-1R modulator C5
      T61483421578-93-0
      GLP-1R modulator C5 is a small molecule GLP-1R orthosteric modulator that enhances GLP-1 binding to GLP-1R via transmembrane sites and can be used in the study of type II diabetes.
      • $35
      In Stock
      Size
      QTY
      SPM-242
      T28838
      SPM-242 is an orthosteric agonist of Sphingosine 1-phosphate (S1P) and a bitopic antagonist. S1P is a lysophospholipid signaling molecule that regulates important biological functions, including vascular development and lymphocyte trafficking, by activat
      • Inquiry Price
      Size
      QTY
      CYM2503
      T89631308833-36-4
      CYM2503 is a positive allosteric modulator (PAM) of the GAL2 receptor that potentiates galanin-induced IP1 production in vitro. It has no affinity for the orthosteric galanin binding site of the receptor (as measured by its inability to displace iodinated galanin, or to induce IP1 accumulation on its own).
      • $51
      In Stock
      Size
      QTY
      (R)-PF-06256142
      T727441609583-15-4
      (R)-PF-06256142, the R enantiomer of PF-06256142, exhibits low activity. PF-06256142 itself is distinguished as a potent and selective orthosteric D1 receptor agonist, with the capability to minimize receptor desensitization compared to dopamine and other catechol-containing agonists.
      • $1,400
      6-8 weeks
      Size
      QTY
      LON63114
      T711791229363-11-4
      LON63114, also known as FFA2-Agonist-1 is a selective orthosteric agonist of human FFA2. FFA2-Agonist-1 is potentially useful in the treatment of gastrointestinal disorders and inflammatory bowel diseases. LON63114 was reported in WO2011076732. This product has no formal name at the moment. For the convenience of communication, a temporal code name was therefore proposed according to MedKoo Chemical Nomenclature (see web page: https://www.medkoo.com/page/naming).
      • $1,670
      6-8 weeks
      Size
      QTY
      CB1R Allosteric modulator 2
      T612762513102-64-0
      CB1R Allosteric modulator 2 (compound 18) is a potent allosteric modulator of the CB1R receptor. It exhibits negative modulation of the functional activity of orthosteric ligands (NAM) at CB1Rs, as demonstrated in previous studies [1].
      • $1,520
      6-8 weeks
      Size
      QTY